Antipsychotic medication prescribing in children enrolled in medicaid

Pediatrics

Volumn 135, Issue 4, 2015, Pages 658-665

  Rettew, David C ^a,b   Greenblatt, Jeanne ^a,b   Kamon, Jody ^b   Neal, Diane ^c   Harder, Valerie ^b   Wasserman, Richard ^b   Berry, Patricia ^b   MacLean, Charles D ^a   Hogue, Nancy ^d   McMains, William ^e  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b Vermont Child Health Improvement Program   (United States)

^c Catamaran Corporation   (United States)

^d Catamaran ^*  (United States)

^e Vermont Department of Mental Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGGRESSION; ARTICLE; CHILD; COGNITIVE THERAPY; DRUG MONITORING; DRUG USE; FEMALE; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTITIONER; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; METABOLIC MONITORING; MOOD DISORDER; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; TREATMENT INDICATION; TREATMENT REFUSAL; UNITED STATES; CLINICAL PRACTICE; COOPERATION; DRUG UTILIZATION; HEALTH SURVEY; INTERDISCIPLINARY COMMUNICATION; MEDICAID; PSYCHIATRY; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; COOPERATIVE BEHAVIOR; DRUG MONITORING; DRUG UTILIZATION; GUIDELINE ADHERENCE; HEALTH SURVEYS; HUMANS; INTERDISCIPLINARY COMMUNICATION; MEDICAID; PHYSICIAN'S PRACTICE PATTERNS; PSYCHIATRY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84927750890     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-2260     Document Type: Article

References (22)

1. Zito JM, Safer DJ, Valluri S, Gardner JF, Korelitz JJ, Mattison DR. Psychotherapeutic medication prevalence in Medicaid-insured preschoolers. J Child Adolesc Psychopharmacol. 2007;17(2):195-203
2. Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005;44(6):548-556
3. Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49(1):13-23
4. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679-685
5. Medco Health Solutions. America's state of mind: a report by Medco. 2011. Available at: http://apps.who.int/medicinedocs/documents/s19032en/s19032en.pdf
6. United States Government Accountability Office. Children's Mental Health: Concerns Remain about Appropriate Services for Children in Medicaid and Foster Care. GAO-13-15. Washington, DC: United States Government Accountability Office; January 9, 2013
7. Zito JM, Burcu M, Ibe A, Safer DJ, Magder LS. Antipsychotic use by Medicaidinsured youths: impact of eligibility and psychiatric diagnosis across a decade. Psychiatr Serv. 2013;64(3):223-229
8. Institute for Health, Health Care Policy and Aging Research at Rutgers, The State University of New Jersey, Center for Education and Research on Therapeutics (CERTs). Antipsychotic medication use in Medicaid children and adolescents: report and resource guide from a 16-state study. Available at: http://rci.rutgers.edu/~cseap/MMDLNAPKIDS.html
9. Pathak P, West D, Martin BC, Helm ME, Henderson C. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61(2):123-129
10. Burcu M, Zito JM, Ibe A, Safer DJ. Atypical antipsychotic use among medicaidinsured children and adolescents: duration, safety, and monitoring implications. J Child Adolesc Psychopharmacol. 2014;24(3):112-119
11. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the officebased treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247-1256
12. Laita P, Cifuentes A, Doll A, et al. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol. 2007;17(4):487-502
13. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of secondgeneration antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144-158
14. Doey T, Handelman K, Seabrook JA, Steele M. Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry. 2007;52(6):363-368
15. Pandina GJ, Aman MG, Findling RL. Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol. 2006;16(4):379-392
16. Findling RL, Reed MD, O'Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(7):792-800
17. Charach A, Carson P, Fox S, Ali MU, Beckett J, Lim CG. Interventions for preschool children at high risk for ADHD: a comparative effectiveness review. Pediatrics. 2013;131 (5). Available at: www.pediatrics.org/cgi/content/full/131/5/e1584
18. Steiner H, Remsing L; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):126-141
19. Weisz JR. Agenda for child and adolescent psychotherapy research: on the need to put science into practice. Arch Gen Psychiatry. 2000;57(9):837-838
20. Constantine R, Bengtson MA, Murphy T, et al. Impact of the Florida Medicaid prior-authorization program on use of antipsychotics by children under age six. Psychiatr Serv. 2012;63(12):1257-1260
21. Morrato EH, Nicol GE, Maahs D, et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med. 2010;164(4):344-351
22. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and metaanalysis of screening practices. Psychol Med. 2012;42(1):125-147